Display options
Cite
Park HJ, Park NC, Kim TN, et al. Discontinuation of Dapoxetine Treatment in Patients With Premature Ejaculation: A 2-Year Prospective Observational Study. Sex Med. 2017;5(2):e99-e105doi: 10.1016/j.esxm.2017.02.003.
Park, H. J., Park, N. C., Kim, T. N., Baek, S. R., Lee, K. M., & Choe, S. (2017). Discontinuation of Dapoxetine Treatment in Patients With Premature Ejaculation: A 2-Year Prospective Observational Study. Sexual medicine, 5(2), e99-e105. https://doi.org/10.1016/j.esxm.2017.02.003
Park, Hyun Jun, et al. "Discontinuation of Dapoxetine Treatment in Patients With Premature Ejaculation: A 2-Year Prospective Observational Study." Sexual medicine vol. 5,2 (2017): e99-e105. doi: https://doi.org/10.1016/j.esxm.2017.02.003
Park HJ, Park NC, Kim TN, Baek SR, Lee KM, Choe S. Discontinuation of Dapoxetine Treatment in Patients With Premature Ejaculation: A 2-Year Prospective Observational Study. Sex Med. 2017 Jun;5(2):e99-e105. doi: 10.1016/j.esxm.2017.02.003. Epub 2017 Apr 05. PMID: 28395997; PMCID: PMC5440632.
Copy Download .nbib Format: NLM
Share it on

Sex Med. 2017 Jun;5(2):e99-e105. doi: 10.1016/j.esxm.2017.02.003. Epub 2017 Apr 05.

Discontinuation of Dapoxetine Treatment in Patients With Premature Ejaculation: A 2-Year Prospective Observational Study.

Sexual medicine

Hyun Jun Park, Nam Cheol Park, Tae Nam Kim, Seung Ryong Baek, Kyung Min Lee, Sangmin Choe

Affiliations

  1. Department of Urology and Medical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea. Electronic address: [email protected].
  2. Department of Urology and Medical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea.
  3. Department of Clinical Pharmacology and Therapeutics, Pusan National University Hospital, Busan, Korea.

PMID: 28395997 PMCID: PMC5440632 DOI: 10.1016/j.esxm.2017.02.003

Abstract

INTRODUCTION: Although dapoxetine is the only oral pharmacologic agent approved for the treatment of premature ejaculation (PE) and is very effective, the discontinuation rate is high.

AIM: To assess the discontinuation rate of patients with PE and the reasons for discontinuation in real-world practice.

METHODS: In total, 182 consecutive patients were enrolled. Type of PE, self-estimated intravaginal ejaculation latency time, and medical history were evaluated in all patients who also completed the erectile function domain of the International Index of Erectile Function (IIEF). Visits were scheduled 1, 3, 6, 12, and 24 months after initiation of therapy; treatment status and the reasons for discontinuation in those who did discontinue were checked. The relations of discontinuation rates were compared with various parameters and the time to discontinuation after treatment commencement.

RESULTS: Of all patients, 9.9% continued treatment to 2 years. The cumulative discontinuation rates at 1, 3, 6, 12, and 24 months were 26.4%, 61.6%, 79.1%, 87.3%, and 90.1%, respectively. Moreover, 79.1% of all patients discontinued treatment within 6 months. After 12 months, the discontinuation rate decreased sharply. The reasons for discontinuation were cost (29.9%), disappointment that PE was not curable and that dapoxetine was required every time sexual intercourse was contemplated (25%), side effects (11.6%), perceived poor efficacy (9.8%), a search for other treatment options (5.5%), and unknown (18.3%). Patients with acquired PE (vs lifelong PE), with intravaginal ejaculation latency time longer than 2 minutes before treatment, on phosphodiesterase type 5 inhibitors, and with IIEF erectile function scores lower than 26 tended to discontinue early and thus exhibited high dropout rates.

CONCLUSION: The treatment discontinuation rate of dapoxetine was very high. The main reasons for discontinuation were the cost and disappointment that treatment was required every time adequate sexual function was required. Park HJ, Park NC, Kim TN, et al. Discontinuation of Dapoxetine Treatment in Patients With Premature Ejaculation: A 2-Year Prospective Observational Study. Sex Med 2017;5:e99-e105.

Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Keywords: Compliance; Premature Ejaculation; Serotonin Uptake Inhibitors

References

  1. J Sex Med. 2004 Sep;1(2):225-32 - PubMed
  2. Eur Urol. 2009 Apr;55(4):967-8 - PubMed
  3. J Sex Med. 2014 Jun;11(6):1392-422 - PubMed
  4. Core Evid. 2012;7:1-14 - PubMed
  5. Int J Impot Res. 2015 Mar-Apr;27(2):75-80 - PubMed
  6. Asian J Androl. 2014 Sep-Oct;16(5):725-7 - PubMed
  7. BJU Int. 2006 Feb;97(2):311-5 - PubMed
  8. J Sex Med. 2010 Jun;7(6):2231-42 - PubMed
  9. J Sex Med. 2011 Feb;8(2):524-39 - PubMed
  10. Int J Clin Pract. 2015 Nov;69(11):1326-33 - PubMed
  11. Maturitas. 2011 Sep;70(1):26-33 - PubMed
  12. Eur Urol. 2014 Apr;65(4):733-9 - PubMed
  13. J Clin Pharmacol. 2006 Mar;46(3):301-9 - PubMed
  14. Arch Sex Behav. 1985 Dec;14(6):467-89 - PubMed
  15. Sex Med Rev. 2015 Jul;3(3):183-202 - PubMed
  16. Eur Urol. 2009 Apr;55(4):957-67 - PubMed
  17. Lancet. 2006 Sep 9;368(9539):929-37 - PubMed
  18. J Sex Med. 2013 Nov;10(11):2832-41 - PubMed
  19. Urol Int. 2016;97(1):104-11 - PubMed
  20. Eur Urol. 2016 May;69(5):904-16 - PubMed
  21. J Sex Med. 2016 Feb;13(2):194-9 - PubMed
  22. J Sex Med. 2012 Sep;9(9):2361-9 - PubMed
  23. J Sex Med. 2009 Oct;6(10):2868-77 - PubMed
  24. BJU Int. 2009 Mar;103(5):651-8 - PubMed
  25. J Sex Med. 2010 Jan;7(1 Pt 1):256-68 - PubMed
  26. Sex Med. 2016 Mar;4(1):e18-27 - PubMed
  27. Neuropsychopharmacology. 2008 May;33(6):1259-65 - PubMed
  28. Urology. 2013 Sep;82(3):620-4 - PubMed
  29. Behav Res Ther. 1986;24(6):665-75 - PubMed

Publication Types